HB Wealth Administration LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT – Get Score ) by 3.4% within the fourth quarter, based on the corporate in its most up-to-date 13F submitting with the Securities and Change Fee. The agency owned 82,203 shares of the healthcare product maker’s inventory after buying a further 2,716 shares throughout the interval. HB Wealth Administration LLC’s holdings in Abbott Laboratories had been price $9,025,000 as of its most up-to-date SEC submitting.

Trendy choices buying and selling for inexperienced persons! (From Tradewins)

A number of different hedge funds have additionally lately made adjustments to their positions in ABT. JDM Monetary Group LLC acquired a brand new stake in Abbott Laboratories throughout the fourth quarter valued at roughly $26,000. EdgeRock Capital LLC bought a brand new stake in Abbott Laboratories within the third quarter valued at roughly $29,000. Glassy Mountain Advisors Inc. bought a brand new stake in Abbott Laboratories within the fourth quarter valued at roughly $44,000. Trifecta Capital Advisors LLC bought a brand new stake in Abbott Laboratories within the fourth quarter valued at roughly $50,000. Lastly, Newbridge Monetary Providers Group Inc. elevated its holdings in Abbott Laboratories by 148.4% within the third quarter. Newbridge Monetary Providers Group Inc. now owns 477 shares of the well being merchandise maker’s inventory valued at $46,000 after shopping for a further 285 shares within the final quarter. 72.93% of the share is owned by institutional traders.

Insiders place their bets

In different information, EVP Andrea F. Wainer offered 679 shares of the inventory in a transaction dated Wednesday, March 1st. The shares had been offered at a mean worth of $100.70, for a complete transaction of $68,375.30. Following the sale, the manager vice chairman now straight owns 70,427 shares of the corporate’s inventory, valued at roughly $7,091,998.90. The transaction was disclosed in a submitting with the SEC, which is accessible at this hyperlink. In different Abbott Laboratories information, EVP Andrea F. Wainer offered 679 shares of the agency’s inventory in a transaction that occurred on Wednesday, March 1st. The shares had been offered at a mean worth of $100.70, for a complete worth of $68,375.30. Following the transaction, the manager vice chairman now straight owns 70,427 shares of the corporate’s inventory, valued at roughly $7,091,998.90. The transaction was disclosed in a submitting with the Securities & Change Fee, which is accessible on the SEC web site. Additionally, SVP Randel William Woodgrift offered 1,032 shares of the agency’s inventory in a transaction that occurred on Wednesday, March 1st. The inventory was offered at a mean worth of $100.70, for a complete transaction of $103,922.40. Following the completion of the transaction, the senior vice chairman now straight owns 52,203 shares within the firm, valued at $5,256,842.10. The details about this sale will be discovered right here. Within the final three months, insiders have offered 1,971 shares of firm inventory valued at $199,140. Firm insiders personal 0.52% of the corporate’s shares.

Analyst Upgrades and Downgrades

ABT has been the topic of plenty of analysis analyst experiences. Stifel Nicolaus boosted their goal worth on Abbott Laboratories from $110.00 to $125.00 and gave the inventory a “purchase” ranking in a report on Thursday, January twenty sixth. Morgan Stanley boosted their worth goal on Abbott Laboratories from $117.00 to $133.00 and gave the corporate an “chubby” ranking in a report on Friday, January sixth. Raymond James boosted their worth goal on Abbott Laboratories from $109.00 to $123.00 and gave the corporate an “outperform” ranking in a report on Thursday, January twenty sixth. Sanford C. Bernstein boosted their worth goal on Abbott Laboratories from $125.00 to $132.00 and gave the corporate an “outperform” ranking in a report on Thursday, January twenty sixth. Lastly, Citigroup boosted their worth goal on Abbott Laboratories from $114.00 to $125.00 and gave the corporate a “purchase” ranking in a report on Monday, December twelfth. One analyst has rated the inventory with a promote ranking, three have given a maintain ranking and eleven have assigned a purchase ranking to the corporate. In accordance with information from MarketBeat, the inventory presently has a mean ranking of “Average Purchase” and a consensus worth goal of $124.67.

Abbott Laboratories down 0.7%

Shares of NYSE ABT traded down $0.67 throughout buying and selling hours on Tuesday, reaching $97.79. The inventory had a turnover of 631,620 shares in comparison with its common quantity of 5,051,245. The corporate has a present ratio of 1.63, a fast ratio of 1.23 and a debt ratio of 0.39. The agency has a market cap of $169.95 billion, a price-to-earnings ratio of 25.18, a P/E/G ratio of 4.40 and a beta of 0.68. The corporate’s fifty day shifting common worth is $104.98 and its 2 hundred day shifting common worth is $104.63. Abbott Laboratories has a 52-week low of $93.25 and a 52-week excessive of $124.36.

Abbott Laboratories (NYSE:ABT – Get Score ) final launched its earnings outcomes on Wednesday, January twenty fifth. The well being merchandise maker reported earnings of $1.03 per share. per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.13. Abbott Laboratories had a return on fairness of 26.09% and a internet margin of 15.88%. The corporate had income of $10.09 billion for the quarter, in comparison with analyst estimates of $9.69 billion. In the identical quarter within the earlier yr, the corporate earned $1.32 in earnings per share. Abbott Laboratories’ income fell 12.0% yr over yr. analysts anticipate that Abbott Laboratories will put up 4.38 EPS for the present fiscal yr.

Abbott Laboratories Dividend Announcement

The corporate additionally lately declared a quarterly dividend, which can be paid on Monday, Might fifteenth. Stockholders of file on Friday, April 14th can be given a dividend of $0.51 per share. This represents an annual dividend of $2.04 and a yield of two.09%. The ex-dividend date is Thursday, April 13. Abbott Laboratories’s dividend yield is at present 52.17%.

About Abbott Laboratories

(Get ranking)

Abbott Laboratories engages within the discovery, growth, manufacture and sale of a broad and diversified line of healthcare merchandise. It operates by means of the next enterprise segments: Established Prescription drugs, Diagnostics, Dietary Merchandise and Medical Units. The Established Pharmaceutical Merchandise phase refers back to the worldwide gross sales of a spread of branded generic pharmaceutical merchandise.

Learn extra

Need to see what different hedge funds have ABT? Go to HoldingsChannel.com for the most recent 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Get Score).

This prompt information alert was generated by narrative science know-how and monetary information from MarketBeat to offer readers with the quickest and most correct reporting. This story was reviewed by MarketBeat editorial workers previous to publication. Please ship questions or feedback about this story to contact@marketbeat.com.

Earlier than you contemplate Abbott Laboratories, you may need to hear this.

MarketBeat retains observe of Wall Avenue’s top-rated and best-performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Abbott Laboratories wasn’t on the record.

Whereas Abbott Laboratories at present has a “Average Purchase” ranking amongst analysts, high rated analysts consider these 5 shares are higher buys.

See the 5 shares right here